Pfizer’s CTI for NIH Researchers

Researcher in a labNCATS led an innovative collaboration for the NIH with Pfizer’s Centers for Therapeutic Innovation (CTI) from 2014 to 2019. The CTI collaboration, which was governed by a steering committee, enabled NIH and Pfizer scientists to identify biologic compounds with activity in a pathway or target of interest and move these compounds through laboratory testing and into clinical evaluation.


A cooperative research and development agreement (CRADA) collaboration with CTI included, among other things, access to Pfizer’s drug development enterprise and publishing rights. It was the first NIH-wide biologics initiative with a pharmaceutical partner that NCATS coordinated on behalf of all NIH intramural researchers.